TrovaGene Inc (NASDAQ:TROV) Short Interest Update

Share on StockTwits

TrovaGene Inc (NASDAQ:TROV) saw a large drop in short interest in June. As of June 30th, there was short interest totalling 464,400 shares, a drop of 10.6% from the May 30th total of 519,300 shares. Currently, 11.6% of the shares of the stock are short sold. Based on an average daily volume of 375,900 shares, the short-interest ratio is currently 1.2 days.

Shares of NASDAQ TROV traded down $0.10 during trading on Friday, hitting $2.15. 64,672 shares of the company were exchanged, compared to its average volume of 52,060. TrovaGene has a 12-month low of $2.14 and a 12-month high of $9.65. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.76 and a quick ratio of 3.76. The company’s fifty day moving average is $2.68. The stock has a market cap of $11.70 million, a price-to-earnings ratio of -0.26 and a beta of 0.77.

TrovaGene (NASDAQ:TROV) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.05. TrovaGene had a negative return on equity of 121.65% and a negative net margin of 3,540.91%. The business had revenue of $0.16 million for the quarter. On average, analysts anticipate that TrovaGene will post -4.02 EPS for the current year.

A number of research analysts have weighed in on TROV shares. Maxim Group set a $8.00 price objective on TrovaGene and gave the company a “buy” rating in a report on Thursday, May 23rd. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. Zacks Investment Research lowered Farmers & Merchants Bancorp, Inc. (OH) from a “hold” rating to a “strong sell” rating in a report on Thursday, May 9th. Finally, Noble Financial set a $2.00 price objective on Pyxis Tankers and gave the company a “buy” rating in a report on Friday, May 24th.

About TrovaGene

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

Recommended Story: Why Net Income is Important to Investors

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Footy Cash   Trading 5.8% Lower  Over Last Week
Footy Cash Trading 5.8% Lower Over Last Week
Aspen Group  vs. Sunlands Online Education Group  Critical Survey
Aspen Group vs. Sunlands Online Education Group Critical Survey
Electroneum  Trading 2.7% Higher  Over Last 7 Days
Electroneum Trading 2.7% Higher Over Last 7 Days
JPMorgan Chase & Co. Lowers News  to Underweight
JPMorgan Chase & Co. Lowers News to Underweight
Bayerische Motoren Werke  Receives Buy Rating from Credit Suisse Group
Bayerische Motoren Werke Receives Buy Rating from Credit Suisse Group
$86.04 Million in Sales Expected for Pennsylvania R.E.I.T.  This Quarter
$86.04 Million in Sales Expected for Pennsylvania R.E.I.T. This Quarter


 
© 2006-2019 Zolmax.